VALIDATE Network
@NetworkValidate
Followers
1K
Following
2K
Media
718
Statuses
7K
International network of researchers aiming to accelerate vaccine development for TB, leishmaniasis, melioidosis &leprosy. Led by @UniofOxford - open to all
Oxford, England
Joined July 2017
Cutaneous leishmaniasis affects hundreds of thousands every year, yet few people have heard of it. Join us on 25 February at the Royal Institution to explore the science behind this neglected disease. Please help spread the word. More info:
validate-network.org
What if a single insect bite could leave a permanent mark — not just on your skin, but on your life? - A free public talk from the VALIDATE Network
0
1
0
Paper: Inflammasome Activation Differences Underpin Different Mycobacterium tuberculosis Infection Outcomes https://t.co/mKp4eU2AxK
onlinelibrary.wiley.com
Summary: PAMPS of Mtb interacts with PRRs of host cells and activates intracellular signaling, leading to activation of the inflammasome complex, which differentially contributes to the progressive...
0
0
0
Tuberculosis: Scientists develop novel drug candidate for combating resistant pathogens - https://t.co/reqCL9DYKV
#GoogleAlerts
medicaldialogues.in
Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting bacteria that cause tuberculosis. The team have produced a compound that...
0
0
0
Eleven clinical trials that will shape medicine in 2026 - Nature - https://t.co/T26a104TBK
#GoogleAlerts
nature.com
Nature Medicine - Nature Medicine asks leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and...
0
0
0
Polish expert warns tuberculosis still a threat - English Section - Polskie Radio - https://t.co/ceotIKhC3Z
#GoogleAlerts
polskieradio.pl
A Polish lung specialist has reminded the public that tuberculosis, while less contagious than flu, still threatens vulnerable people and requires long, careful treatment.
0
0
0
What if a single insect bite could leave a lifelong scar? Discover the science and human stories behind leishmaniasis at our free public talk with Dr María Adelaida Gómez on 25 February, 19:00, Royal Institution. Details: https://t.co/mZeZQUcFE5
0
1
0
Global tuberculosis response off track: urgent priorities to end the world's top infectious kil - https://t.co/CthSJgWXhy
#GoogleAlerts
thelancet.com
Despite progress and advances in diagnostics and treatments, tuberculosis remains the world's leading cause of death from an infectious disease.1,2 The WHO Global Tuberculosis Report 2025 reveals...
0
1
0
India’s progress against TB is real, but not rapid enough https://t.co/ISaHl9FoaM via @IndianExpress
indianexpress.com
According to WHO Global Tuberculosis Report 2025, steep drop in global funding, persistent care gaps and weak awareness threaten India’s promise to eliminate the disease five years ahead of the rest...
0
1
0
Dr María Adelaida Gómez has witnessed the social and psychological effects of leishmaniasis firsthand in rural Colombia. Her talk will explore why the disease persists and how science can change lives. Please share this event. Event info: https://t.co/mZeZQUc7Ox
0
1
2
As Co-Director of VALIDATE, Dr Gómez leads global efforts to accelerate vaccine research for neglected diseases. Hear Adelaida's perspective on Leishmaniasis and the development of vaccines at the Royal Institution. Help spread the word. Details:
validate-network.org
What if a single insect bite could leave a permanent mark — not just on your skin, but on your life? - A free public talk from the VALIDATE Network
0
2
2
Join Colombian biomedical scientist Dr María Adelaida Gómez as she reveals the human and scientific story behind cutaneous leishmaniasis on 25 February at the Royal Institution. Please share this event to help us reach a wider audience. More info:
validate-network.org
What if a single insect bite could leave a permanent mark — not just on your skin, but on your life? - A free public talk from the VALIDATE Network
0
0
0
#Article in @MedComm_MC Inflammasome Activation Differences Underpin Different Mycobacterium tuberculosis Infection Outcomes https://t.co/P0y38l8vJi, studied by @selva_trc and his group from @RutgersMens
#HostPathogenInteractions #ImmuneResponse #infection #tuberculosis
0
1
0
Very happy to share our group’s second publication this month! In this work, we investigate the intrinsic anti-tuberculosis activity of polymeric β-cyclodextrin nanoparticles. Proud of the team’s efforts!
0
2
6
An outer membrane vesicle vaccine prevents lung pathology in a macaque model of ... - Nature - https://t.co/JOcFnG1kjK
#GoogleAlerts
nature.com
Nature Communications - Currently, there is no licensed vaccine for Burkholderia pseudomallei, the causative agent of melioidosis. Here, the authors evaluate the efficacy and safety of an...
0
1
0
Tuberculosis (TB) that doesn’t respond to standard drugs is called drug-resistant TB and emerges when TB medicines are used inappropriately. Although the number of people developing drug-resistant TB has declined since 2015, it remains a global public health crisis affecting 390
5
12
41
#Tuberculosis (TB) is preventable and curable. Yet, it remains one of the world’s deadliest infectious killers, claiming 1.23 million lives in 2024. The WHO Global Tuberculosis Report 2025 talks about the gains made so far and the challenges ahead due to severe funding cuts:
36
129
236
Paper: Diagnostic value of five Mycobacterium tuberculosis dormant highly expressed antigens in latent infections and immunogenicity assessment of a novel subunit vaccine PB2-DIMQ https://t.co/ZzGUAIHKNB
0
0
0
Paper: Targeting HspX of Mycobacterium tuberculosis: Advances in diagnostics,...
0
0
0
Protara’s cell therapy touts BCG-naïve treatment potential in Phase II https://t.co/aPy7av4Snf via @TrialsArena
clinicaltrialsarena.com
If Protara's cell therapy TARA-002 reached the market, it would become the first drug to gain approval in the BCG-naïve setting of NMIBC.
0
0
0